Insulet’s Chief Technology Officer Mark Field leaves for new opportunities in the drug delivery industry
Insulet, a leader in automated insulin delivery technology, recently announced the departure of their Senior Vice President and Chief Technology Officer, Mark Field. Field left his position at Insulet to pursue new opportunities, effective March 14. While the company searches for a replacement, it named Amit Guliani as an interim CTO.
Field originally joined Insulet in 2019 after serving as CTO at Thermo Fisher. His primary focus was on expanding the engineering team and advancing the development of the Omnipod 5 automated insulin delivery system. Field highlighted his journey at Insulet and the Omnipod 5 during a presentation at DeviceTalks West in Santa Clara, California, in 2023.
During his tenure at Insulet, Field played a crucial role in launching the latest automated insulin delivery (AID) system. Omnipod 5 offers innovative SmartAdjust technology, utilizing CGM readings to anticipate blood glucose levels up to an hour in advance. By monitoring and adjusting insulin delivery based on the user’s predefined glucose targets, Omnipod 5 ensures personalized and effective treatment.
Omnipod 5 initially received FDA clearance in 2022 for individuals aged two and above with Type 1 diabetes, making it the first system of its kind in the market. Last August, Insulet expanded approval to include Type 2 diabetes patients. Field’s efforts were instrumental in advancing this cutting-edge technology to benefit a broader patient population.
Insulet expressed its gratitude to Field, acknowledging his essential contributions to the company’s technological advancements. Field will receive standard severance benefits as detailed in Insulet’s executive severance plan. The company plans to enter into a consulting agreement with Field to facilitate a seamless transition.
While Field has moved on to pursue new endeavors, Amit Guliani has been appointed as the interim CTO to oversee Insulet’s technology initiatives. As the search continues for a permanent replacement, Insulet remains committed to maintaining the company’s high standards of technological innovation and product development.
The departure of Mark Field signifies a new chapter for Insulet. Despite this change in leadership, Insulet remains dedicated to advancing its automated insulin delivery systems and providing state-of-the-art solutions for individuals living with diabetes. Insulet has expanded the availability of the Omnipod 5 system to more countries, emphasizing its commitment to improving patient care worldwide.
